2 June 2026
We are pleased to invite you to the Medicines Patent Pool webinar on the Expression of Interest (EOI) process for baloxavir marboxil licence.
This session will provide a comprehensive overview of the EOI process and the opportunity to engage directly with the MPP team.
Date: Friday, 12 June 2026Time: 13:00–14:30 CET / 16:30–18:00 ISTFormat: Virtual meeting
Register here
We strongly encourage interested companies and product developers to attend and take part in the discussion.
Medicines Patent Pool is inviting Expressions of Interest (EOIs) from potential sublicensees for the manufacture and sale of baloxavir in the licensed territory. By granting multiple sublicences, MPP aims to support sustainable supply, broaden access, and promote competitive pricing for essential medicines.
Applicants are invited to complete an online EOI form, which serves as a proposal to use licensed intellectual property to develop or improve access to relevant medicines in eligible countries under the licence framework.
For more information on the EOI process and current opportunities related to baloxavir marboxil, please refer to the EOI portal.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.